Updates are available Correction dated 2023-08-24

Article History

Received: 30 September 2021

Revised: 5 August 2022

Accepted: 31 August 2022

First Online: 8 October 2022

Change Date: 24 August 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41391-023-00683-1

Competing interests

: MRS reports travel expenses from and an advisory role for Amgen; research funding and travel expenses from and an advisory role for Bayer; research funding and travel expenses from and an advisory role for Janssen; travel expenses and an advisory role for Lilly; and an advisory role for Novartis and Pfizer. FS reports honoraria from AbbVie and Amgen; consultancy for and research funding and honoraria from Astellas, AstraZeneca/MedImmune, Bayer, Janssen, and Sanofi; and research funding from Bristol Myers Squibb and Pfizer. SC reports consultancy and speakers bureau participation for and honoraria and travel expenses from Astellas Pharma, Bayer, Beigene, Clovis Oncology, Janssen-Cilag, Johnson & Johnson, Novartis, and Sanofi; and research funding from Clovis Oncology. SO reports consultancy for and honoraria from Astellas; consultancy for and travel expenses and honoraria from Bayer, Bristol Myers Squibb, Eisai Merck, Sharp & Dohme, Novartis, and Pfizer; research funding from Ipsen; consultancy for and honoraria from Janssen; and consultancy for and research funding and honoraria from Sanofi. BH reports research funding from German Cancer Aid and the German Research Foundation; consultancy for and research funding and travel expenses from Janssen; consultancy for and travel expenses from Astellas and Bayer; research funding and royalties from Uromed; and consultancy for ABX, Pfizer, and Lightpoint Medical, Inc. DO reports advisory roles for AstraZeneca, Bayer, Clovis Oncology, Daiichi-Sankyo, Janssen, MSD, and Genentech/Roche; compensation for travel from Bayer, Ipsen, Janssen, and Genentech/Roche; honoraria from Bayer, Janssen, and Sanofi; and research funding from Astellas, AstraZeneca, Bayer, Genentech/Roche, Janssen, Pfizer, Medivation, MSD, and Pfizer. HU reports honoraria and travel expenses from Janssen; honoraria from Astellas; consultancy for and honoraria and travel expenses from Takeda; honoraria and travel expenses from Sanofi and Bayer; and consultancy for AstraZeneca. EJS reports an advisory role for and stock in Fortis; stock in Harpoon Therapeutics; honoraria for speaking engagements and an advisory role for Janssen; honoraria from Johnson & Johnson for speaking engagements; and consultancy or as an advisory board member for Teon Therapeutics, Ultragenyx, Beigene, and Tolero. AB, AL, BR, SB-M, PD, and SDM report that they are employees of Janssen and hold stock in Johnson & Johnson. JYL and YP have no conflicts to disclose.